Edgewood Oncology, Inc.
1 known investors
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a small molecule multi-kinase inhibitor that co-targets master regulators of cancer to trigger programmed cell death. Its clinical programs focus on hematologic malignancies and genetically-defined solid tumors, including GATA3-mutant breast cancer.
Investors · 1
Frequently asked questions
- What does Edgewood Oncology, Inc. do?
- Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a small molecule multi-kinase inhibitor that co-targets master regulators of cancer to trigger programmed cell death. Its clinical programs focus on hematologic malignancies and genetically-defined solid tumors, including GATA3-mutant breast cancer.
- Who are Edgewood Oncology, Inc.'s investors?
- Edgewood Oncology, Inc.'s investors include Alta Partners.